<DOC>
	<DOCNO>NCT03075072</DOCNO>
	<brief_summary>This research study study two different type radiation treatment brain metastasis ( tumor brain spread cancer originate elsewhere body )</brief_summary>
	<brief_title>Whole Brain Radiation Versus Stereotactic Radiation ( SRS ) Patients With 5-15 Brain Metastases : A Phase III , Randomized Clinical Trial</brief_title>
	<detailed_description>This research study Phase III clinical trial . Phase III clinical trial examine safety effectiveness treatment , often compare another know treatment . In case , investigator specifically look difference two form radiation treatment term subsequent quality life . In research study , investigator compare stereotactic ( focused , pinpoint ) radiation ( tumor narrowly target ) whole brain radiation ( radiation target entire brain ) treatment brain metastasis . Currently whole brain radiation standard option patient 5-15 brain metastasis . Stereotactic radiation standard option patient 1-4 brain metastasis . Among patient 1-4 brain metastasis , recently publish study suggest stereotactic radiation result few neurologic side effect whole brain radiation . It also yield good quality life population . It remain unknown whether stereotactic radiation improve quality life patient 5-15 brain metastasis relative whole brain radiation . In study , investigator seek determine two method study treatment result well subsequent quality life patient 5-15 brain metastasis .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Participants must biopsy proven solid malignancy untreated ( radiation ) intracranial lesion radiographically consistent pathologically proven brain metastasis . Patients undergone prior systemic therapy eligible Fivefifteen intracranial lesion must present MRI brain Age 1880 year diagnosis brain metastasis Karnofsky performance status least 70 ( See Appendix A ) Participants undergone prior radiation brain metastasis . Patients undergone resection one brain metastases yet start adjuvant radiotherapy eligible study Participants undergo brain MRI Participants receive gadolinium ( MRI contrast ) Participants stage IVV chronic kidney disease end stage renal disease Participants widespread , definitive leptomeningeal disease Participants small cell lung cancer , lymphoma , myeloma Participants maximum tumor diameter exceed 5 cm ( resect )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Brain metastasis</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Kidney cancer</keyword>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Stereotactic radiation</keyword>
	<keyword>Stereotactic radiosurgery</keyword>
	<keyword>SRS</keyword>
	<keyword>Stereotactic</keyword>
	<keyword>Whole brain radiation</keyword>
	<keyword>WBRT</keyword>
	<keyword>Hippocampal avoidance</keyword>
	<keyword>Hippocampal spar</keyword>
	<keyword>Hippocampal</keyword>
	<keyword>Hippocampus</keyword>
	<keyword>Radiation</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Neurocognitive</keyword>
	<keyword>Neurocognition</keyword>
	<keyword>Survival</keyword>
	<keyword>Salvage</keyword>
	<keyword>MDASI</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Recurrence</keyword>
</DOC>